Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Thermo Fisher Scientific Inc | TMO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
515.25 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 475.77 - 611.06 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 515.25 | USD |
Thermo Fisher Scientific Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 198.74B | 385.72M | 384.94M | $ 10.71B | $ 12.85M | 3.34 | 33.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.27% | 06/14/23 | -8.70k | - |
Thermo Fisher Scientific News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TMO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 523.49 | 527.16 | 512.60 | 518.40 | 1,819,989 | -8.24 | -1.57% |
1 Month | 523.02 | 534.64 | 498.50 | 518.37 | 1,770,325 | -7.77 | -1.49% |
3 Months | 555.31 | 593.17 | 498.50 | 541.52 | 1,478,267 | -40.06 | -7.21% |
6 Months | 562.11 | 609.85 | 498.50 | 553.27 | 1,449,208 | -46.86 | -8.34% |
1 Year | 547.93 | 611.06 | 475.77 | 545.59 | 1,409,094 | -32.68 | -5.96% |
3 Years | 350.08 | 672.34 | 330.57 | 519.43 | 1,479,325 | 165.17 | 47.18% |
5 Years | 217.63 | 672.34 | 202.83 | 421.13 | 1,496,374 | 297.62 | 136.76% |
Thermo Fisher Scientific Description
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, life science reagents and provides drug testing and manufacturing services. The firm operates through four segments (revenue figures include some cross-segment revenue and adjustments are made for the PPD acquisition and the deceleration of COVID-19 testing revenue): analytical technologies (15% of sales); specialty diagnostic products (14%); life science solutions (27%); and lab products and services (52%). |